Recursion Pharmaceuticals Revenue and Competitors

Claim your profile

Location

#7108

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Recursion Pharmaceuticals's estimated annual revenue is currently $89.8M per year.(i)
  • Recursion Pharmaceuticals received $20.5M in venture funding in June 2018.
  • Recursion Pharmaceuticals's estimated revenue per employee is $201,000
  • Recursion Pharmaceuticals's total funding is $465.4M.

Employee Data

  • Recursion Pharmaceuticals has 447 Employees.(i)
  • Recursion Pharmaceuticals grew their employee count by 96% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$16.1M80-1%N/AN/A
#2
$251.3M12503%N/AN/A
#3
$2.6M13N/AN/AN/A
#4
$3M15N/AN/AN/A
#5
$13.5M67-1%$16.6MN/A
#6
N/A20N/A$66.7MN/A
#7
$3M15N/AN/AN/A
#8
$89.8M44796%$465.4MN/A
#9
$17.5M8728%N/AN/A
#10
$13.7M6836%N/AN/A

Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. Our platform has resulted in the massive parallelization of drug discovery. We have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. We partner or out-license these leads to major pharmaceutical companies early in development. Our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$465.4M

Total Funding

447

Number of Employees

$89.8M

Revenue (est)

96%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Recursion Pharmaceuticals News

2022-04-20 - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells ...

Get Recursion Pharmaceuticals alerts: On Thursday, April 7th, Christopher Gibson sold 36,718 shares of Recursion Pharmaceuticals stock. The...

2022-04-19 - Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to Neutral ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) was downgraded by equities research analysts at Bank of America from a “buy” rating to...

2022-03-22 - Recursion Pharmaceuticals: Q4 Earnings Snapshot

SALT LAKE CITY (AP) _ Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $64.9 million in its fourth quarter.

2020-09-10 - Recursion Raises $239M in Series D Equity Financing

Recursion, a Salt Lake City, UT-based digital biology company industrializing drug discovery, raised $239m in Series D financing. The round was led by Leaps by Bayer, the impact investment arm of Bayer AG, with participation from new investors Casdin Capital, Catalio Capital Management, LP, Lau ...

2020-09-09 - Recursion Pharma nets $239M, plus an AI research contract with Bayer

Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more. Sponsored by Agilent Technologies How would you like to win free bench space ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$118.1M45617%$167.2M
#2
N/A4756%N/A
#3
N/A4950%N/A
#4
$173.5M514N/AN/A
#5
$133M5194%N/A

Recursion Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2015-12-08$2.6MUndisclosedArticle
2016-10-04$12.9MALux CapitalArticle
2016-11-23$2.2MAFelicis VenturesArticle
2017-02-10$4.0MUndisclosedSquare 1 BankArticle
2017-10-04$60.0MBData Collective (DCVC)Article
2018-06-06$20.5MUndisclosedSquare 1 BankArticle